BioResonator receives orders in connection with newly signed distributor agreements
BioResonator signs new orders with several new distributors. As of one month, the company has the official CE approval required to sell their products throughout the European Union.
”The other week we attended at the largest European conference for ophthalmologists (ESCRS) in Paris, and received very positive response. Our instruments ART™ Manual and ART™ Servo Controlled are so simple to use and have such a high precision within glaucoma diagnostics that we are convinced of a strong impact, primarily in the eye specialist group, but also as an important screening and follow up tool in primary health care” says Mikael Lindblad, CEO of Umeå-based company BioResonator AB
The company has already signed contracts with distributors on many of its key markets: Great Britain, Spain, Italy, Holland and on the Scandinavian markets Sweden and Finland. The latest addition to the list of distributors is Topcon in Denmark that will sell BioResonator’s products. Topcon's parent company is in Japan, and they are one of the largest actors in the world in this area. Orders for the company’s products for diagnostics of glaucoma were signed at the conference. BioResonator also received orders for a number of devices intended for clinical studies in the US.
These products are so called tonometers that are used to measure the intraocular pressure (eye pressure). A high IOP can be a sign of glaucoma, a disease that entails permanent damage of the optic nerve and may lead to blindness if it goes untreated. In the Western countries some six per cent of the population over 70 years of age suffers from glaucoma (1). Today the measuring of intraocular pressure is a standard procedure carried out by eye specialists, opticians, health care centers, and private care institutions. Many people could suffer from the disease without knowing it, and are thus unlikely to seek care. The number of undetected cases may be up to 50 per cent (2). People with glaucoma will need life-long care and regular measuring of IOP.
”Our IOP devices are based on a patented technology (resonance technology) and are considerably easier to use than the current, in many ways obsolete, technology which eye clinics are constrained to using today. The BioResonator IOP devices also have the advantage of working on corneas that have undergone laser surgery,” says Mikael Lindblad.
1) Rudnicka AR, Mt-Isa S, Owen CG,Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian metaanalysis. Invest Ophthalmol Vis Sci 2006;47:4254-61.
2) Ekstrom C. Prevalence of open-angle glaucoma in central Sweden. The Tierp Glaucoma Survey. Acta Ophthalmol Scand 1996;74:107-12.
For more information, please contact:
Mikael Lindblad, CEO, +46 730-584620
Email: mikael.lindblad@bioresonator.com
Company chairperson:
Agneta Edberg, Senior Venture Manager, LinkMed AB, +46 70-555 75 18
Email: agneta.edberg@linkmed.se
BioResonator's business concept is to develop and market diagnostic systems based on sensor technology for the health and medical care. BioResonator is owned by LinkMed, Karolinska Development and private entities. Read more about BioResonator at www.bioresonator.com